RISA Labs
Latest round
- Series A
Last raised
- Jan 2026
Total raised
- $15M
Investors
- 6
About RISA Labs
RISA Labs, Inc. develops AI-driven workflow automation solutions focused on enhancing efficiency in oncology clinical operations, particularly in prior authorization processes to improve patient care and operational effectiveness. Founded in 2024 in San Francisco, US, RISA Labs, Inc. provides advanced automation solutions for oncology. RISA Labs was established by a team with experience in healthcare technology but specific founder details are not available. RISA Labs specializes in AI-powered workflow automation solutions aimed at optimizing prior authorization processes within oncology clinical operations. The core offering focuses on intelligent automation that streamlines eligibility checks, medical necessity verification, and prior authorization submissions, effectively mitigating treatment delays for cancer patients. Designed to facilitate operational efficiency, these solutions are utilized by healthcare providers, including hospitals and oncology clinics, allowing their staff to concentrate more on patient care rather than administrative tasks. RISA Labs serves a diverse clientele primarily across the United States, addressing the critical challenges in oncology care caused by fragmented prior authorization processes.RISA Labs generates revenue through a subscription-based model for its workflow automation solutions, which are tailored for oncology practices and healthcare organizations. Clients typically engage in contracts that allow access to the platform, which includes features like auto-populating payer-specific forms and real-time authorization verification. The transactions occur directly between RISA Labs and healthcare providers, ensuring that organizations can optimize their prior authorization processes with minimal disruption. This direct-to-business approach fosters long-term partnerships and sustained revenue streams, particularly as healthcare providers increasingly seek efficient solutions to combat care delays. While specific pricing details for the services are not disclosed, the offerings are designed to provide a comprehensive solution for various types of oncology-related prior authorizations. In January 2026, RISA Labs, Inc. RISA Labs intends to expand into new markets, specifically targeting oncology centers across North America and Europe by the end of 2026.
Who invested in RISA Labs
6 investors across 2 rounds
See all investors in RISA Labs
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about RISA Labs
Who invested in RISA Labs?
RISA Labs has 6 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has RISA Labs raised?
RISA Labs has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did RISA Labs last raise money?
RISA Labs's most recent round on record is a Series A, in Jan 2026.
What does RISA Labs do?
RISA Labs is a software company.
Where is RISA Labs headquartered?
RISA Labs is headquartered in San Francisco, US.
Which VCs invest in companies like RISA Labs?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back software companies at RISA Labs's stage. Their profiles are linked below.
VCs backing software startups at Series A
Raising like RISA Labs? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.